SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

 

Commission file number: 0-21116

 

 

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   ý  No   o

 

The number of shares outstanding of the registrant’s common stock as of May 10, 2002 was 9,667,837.

 

 

USANA HEALTH SCIENCES, INC.

 

FORM 10-Q

 

For the Quarterly Period Ended March 30, 2002

 

INDEX

 

PART I. FINANCIAL INFORMATION
Item 1	Financial Statements
	Consolidated Balance Sheets
	Consolidated Statements of Earnings
	Consolidated Statement of Stockholders’ Equity
	Consolidated Statements of Cash Flows
	Notes to Consolidated Financial Statements
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3	Quantitative and Qualitative Disclosures About Market Risk
PART II. OTHER INFORMATION
Item 5	Other Information
Item 6	Exhibits and Reports on Form 8-K
Signatures

 

2

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

 

(in thousands, except per share data)

 

		December 29, 2001			March 30, 2002
					(unaudited)
ASSETS
Current assets
Cash and cash equivalents		$	2,465		$	3,269
Inventories, net (Note A)		9,533			9,554
Prepaid expenses and other current assets (Note B)		1,441			1,761
Deferred income taxes		750			962
Total current assets		14,189			15,546
Property and equipment, net (Note C)		19,489			18,792
Other assets		1,676			1,654
		$	35,354		$	35,992
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Current maturities of long-term debt		$	2,000		$	2,357
Accounts payable		2,627			2,372
Other current liabilities (Note D)		5,114			7,077
Line of credit		4,098			2,575
Total current liabilities		13,839			14,381
Deferred income taxes		988			756
Long-term debt, less current maturities		6,000			5,143
Stockholders’ equity (Note E)
Common stock, $0.001 par value; authorized 50,000 shares, issued and outstanding 9,664 as of December 29, 2001 and March 30, 2002		10			10
Additional paid-in capital		2,359			2,359
Retained earnings		12,752			13,869
Accumulated other comprehensive loss		(594		)	(526		)
Total stockholders’ equity		14,527			15,712
		$	35,354		$	35,992

 

The accompanying notes are an integral part of these statements.

 

3

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF EARNINGS

 

(in thousands, except per share data)

 

		Quarter Ended
		(unaudited)
		March 31, 2001			March 30, 2002
Net sales		$	27,614		$	28,622
Cost of sales		7,982			7,711
Gross profit		19,632			20,911
Operating expenses:
Associate incentives		10,503			10,730
Selling, general and administrative		7,574			8,055
Research and development		285			199
Total operating expenses		18,362			18,984
Earnings from operations		1,270			1,927
Other income (expense):
Interest income		35			16
Interest expense		(261		)	(100		)
Other, net		(290		)	(12		)
Total other expense		(516		)	(96		)
Earnings before income taxes		754			1,831
Income taxes		283			714
Net earnings		$	471		$	1,117
Earnings per common share (Note E)
Basic		$	0.05		$	0.12
Diluted		$	0.05		$	0.12
Weighted average common and dilutive common equivalent shares outstanding (Note E)
Basic		9,683			9,664
Diluted		9,733			9,671

 

The accompanying notes are an integral part of these statements.

 

4

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

 

Quarters Ended March 31, 2001 and March 30, 2002

 

(in thousands, except per share data)

(unaudited)

 

		Common Stock					Additional Paid-in Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Total
		Shares		Value
For the Quarter Ended March 31, 2001
Balance at December 30, 2000		9,683		$	10		$	2,364		$	10,581		$	(82	)	$	12,873
Comprehensive income
Net earnings		—		—			—			471			—			471
Foreign currency translation adjustment		—		—			—			—			(313		)	(313		)
Comprehensive income																158
Balance at March 31, 2001		9,683		$	10		$	2,364		$	11,052		$	(395	)	$	13,031
For the Quarter Ended March 30, 2002
Balance at December 29, 2001		9,664		$	10		$	2,359		$	12,752		$	(594	)	$	14,527
Comprehensive income
Net earnings		—		—			—			1,117			—			1,117
Foreign currency translation adjustment		—		—			—			—			68			68
Comprehensive income																1,185
Balance at March 30, 2002		9,664		$	10		$	2,359		$	13,869		$	(526	)	$	15,712

 

The accompanying notes are an integral part of this statement.

 

5

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(in thousands, except per share data)

(unaudited)

 

		Quarter Ended
		March 31, 2001			March 30, 2002
Increase (decrease) in cash and cash equivalents
Cash flows from operating activities
Net earnings		$	471		$	1,117
Adjustments to reconcile net earnings to net cash provided by operating activities
Depreciation and amortization		1,007			1,059
Loss on sale of property and equipment		—			18
Deferred income taxes		(15		)	(426		)
Provision for inventory obsolescence		174			426
Changes in operating assets and liabilities:
Inventories		743			(406		)
Income taxes receivable		1,112			—
Prepaid expenses and other assets		407			(253		)
Accounts payable		199			(253		)
Other current liabilities		1,164			1,946
Total adjustments		4,791			2,111
Net cash provided by operating activities		5,262			3,228
Cash flows from investing activities
Purchases of property and equipment		(2,712		)	(386		)
Proceeds from the sale of property and equipment		—			8
Net cash used in investing activities		(2,712		)	(378		)
Cash flows from financing activities
Principal payments of long-term debt		—			(500		)
Decrease in line of credit		(2,653		)	(1,523		)
Net cash used in financing activities		(2,653		)	(2,023		)
Effect of exchange rate changes on cash		(337		)	(23		)
Net increase (decrease) in cash and cash equivalents		(440		)	804
Cash and cash equivalents beginning of period		2,900			2,465
Cash and cash equivalents end of period		$	2,460		$	3,269
Supplemental disclosures of cash flow information
Cash paid during the period for:
Interest		$	368		$	117
Income taxes		180			99

 

The accompanying notes are an integral part of these statements.

 

6

 

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

 

Basis of Presentation

 

The unaudited interim consolidated financial information of USANA Health Sciences, Inc. and Subsidiaries (the “Company” or “USANA”) has been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations.  In the opinion of management, the accompanying interim consolidated financial information contains all adjustments, consisting of normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 30, 2002, and results of operations for the quarters ended March 30, 2002 and March 31, 2001.  These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2001.  The results of operations for the quarter ended March 30, 2002 may not be indicative of the results that may be expected for the fiscal year ending December 28, 2002.

 

 

NOTE A — INVENTORIES

 

Inventories consist of the following:

 

 

		December 29, 2001			March 30, 2002
Raw materials		$	2,314		$	2,382
Work in progress		1,610			1,752
Finished goods		6,438			6,570
		10,362			10,704
Less allowance for inventory obsolescence		829			1,150
		$	9,533		$	9,554

 

 

NOTE B — PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other assets consist of the following:

 

		December 29, 2001			March 30, 2002
Prepaid expenses		$	1,002		$	1,137
Receivables, net		321			502
Other current assets		118			122
		$	1,441		$	1,761

 

7

 

NOTE C - - PROPERTY AND EQUIPMENT

 

Cost of property and equipment and their estimated useful lives is as follows:

 

		Years		December 29, 2001			March 30, 2002
Building		40		$	8,110		$	8,110
Laboratory and production equipment		5-7		4,505			4,509
Computer equipment and software		3-5		15,607			15,813
Furniture and fixtures		3-5		2,099			2,102
Automobiles		3-5		294			296
Leasehold improvements		3-5		1,024			1,030
Land improvements		15		931			931
				32,570			32,791
Less accumulated depreciation and amortization				15,055			16,054
				17,515			16,737
Land				1,773			1,773
Deposits and projects in process				201			282
				$	19,489		$	18,792

 

NOTE D - OTHER CURRENT LIABILITIES

 

Other current liabilities consist of the following:

 

		December 29, 2001			March 30, 2002
Associate incentives		$	682		$	874
Accrued compensation		664			991
Sales taxes		534			616
Income taxes payable		187			1,677
Accrued Associate promotions		313			378
Deferred revenue		727			976
All other		2,007			1,565
		$	5,114		$	7,077

 

8

 

NOTE E — COMMON STOCK AND EARNINGS PER SHARE

 

During 2000, the Company announced and began to implement a share repurchase program, under which it purchased shares of common stock in the open market at market prices.  No shares were purchased during this ongoing repurchase program during the quarter ended March 30, 2002.  However, the Company intends to repurchase shares as circumstances permit.

 

Basic earnings per share are based on the weighted average number of shares outstanding for each period.  Shares redeemed have been included in the calculation of weighted average shares outstanding for basic earnings per share. Diluted earnings per common share are based on shares outstanding (computed under basic EPS) and potentially dilutive shares.  Potential shares included in dilutive earnings per share calculations include stock options granted but not exercised.

 

		For the Quarter Ended
		March 31, 2001			March 30, 2002
Earnings available to common shareholders		$	471		$	1,117
Basic EPS
Shares
Common shares outstanding entire period		9,683			9,664
Weighted average common shares:
Issued during period		—			—
Canceled during period		—			—
Weighted average common shares outstanding during period		9,683			9,664
Earnings per common share — basic		$	0.05		$	0.12
Diluted EPS
Shares
Weighted average shares outstanding during period — basic		9,683			9,664
Dilutive effect of stock options		50			7
Weighted average shares outstanding during period — diluted		9,733			9,671
Earnings per common share — diluted		$	0.05		$	0.12

 

 

Options to purchase 1,741 and 2,480 shares of stock were not included in the computation of EPS for the quarters ended March 31, 2001and March 30, 2002, respectively, due to their exercise price being greater than the average market price of the shares.

 

NOTE F — SEGMENT INFORMATION

 

The Company has four operating segments. The United Kingdom (which, for purposes of this Report, includes The Netherlands) market is serviced from the United States and is considered a part of the domestic operating segment of the Company.  Additionally, the Company has a direct export program for customers in Japan.  These results are also incorporated in the domestic segment.  The Japan segment contains all the results from our operations in Japan that began during the fourth quarter of 2001.

 

The Company’s operating segments are based on operating geographic regions. Management considers the geographic segments of the Company to be the only reportable operating segments.  These operating segments are evaluated regularly by management in determining the allocation of resources and in assessing the performance of the Company.  Management evaluates performance based on sales revenue and the amount of operating income or loss.

 

9

 

Segment profit or loss is based on profit or loss from operations before income taxes.  Interest income and expense as well as income taxes, while significant, are not included in the Company’s determination of segment profit or loss in assessing the performance of a segment.

 

Financial information summarized by geographic segment for the quarters ended March 31, 2001 and March 30, 2002 is listed below:

 

		Revenues from External Customers			Intersegment Revenues			Earnings before Income Taxes			Long-lived Assets			Total Assets
Quarter ended March 31, 2001:
United States		$	16,051		$	2,728		$	1,482		$	27,480		$	37,179
Canada		6,807			—			(179		)	161			2,063
Australia — New Zealand		3,467			222			(512		)	321			3,086
Hong Kong		1,289			—			(122		)	393			1,625
Japan		—			—			—			—			—
Reportable Segments Total		27,614			2,950			669			28,355			43,953
Unallocated and Other (1)		—			(2,950		)	85			(8,162		)	(9,736		)
Consolidated Total		$	27,614		$	—		$	754		$	20,193		$	34,217

 

 

		Revenues from External Customers			Intersegment Revenues			Earnings before Income Taxes			Long-lived Assets			Total Assets
Quarter ended March 30, 2002:
United States		$	15,932		$	3,144		$	2,058		$	23,551		$	32,517
Canada		7,198			—			403			114			2,594
Australia — New Zealand		3,480			269			106			301			3,268
Hong Kong		1,176			—			(121		)	198			1,045
Japan		836			—			(847		)	1,463			2,397
Reportable Segments Total		28,622			3,413			1,599			25,627			41,821
Unallocated and Other (1)		—			(3,413		)	232			(5,181		)	(5,829		)
Consolidated Total		$	28,622		$	—		$	1,831		$	20,446		$	35,992

 

(1)   “Unallocated and Other” includes certain corporate items and eliminations that are not allocated to the operating segments.

 

10

 

Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of USANA’s financial condition and results of operations should be read in conjunction with the Unaudited Consolidated Financial Statements and Notes thereto contained in this quarterly report.

 

General

 

USANA develops and manufactures high-quality nutritional, personal care and weight management products.  USANA distributes its products through a network marketing system in the United States, Canada, Australia, New Zealand, Hong Kong, and Japan.  USANA refers to its independent distributors as Associates.  We also offer a Preferred Customer program specifically designed for customers who desire to purchase USANA’s products for personal use and do not desire to resell or distribute products.  Sales to Preferred Customers accounted for approximately 19% of net sales during the first quarter of 2002.

 

USANA’s three primary product lines consist of USANA^® Nutritionals, LEAN LifelongÔ and SenséÔ. The USANA Nutritionals product line accounted for approximately 67% of net sales for the quarter ended March 30, 2002.  USANA’s top selling products, USANA^® Essentials and Proflavanol^® represented approximately 27% and 11%, respectively, of net sales for the quarter ended March 30, 2002.  The LEAN Lifelong product line accounted for approximately 10% of net sales for the quarter ended March 30, 2002. The LEAN Lifelong product line includes several completely reformulated food products previously sold under the LEAN or USANA brand names.  NutrimealÔ and Fibergy^® drink mixes, Nutribar and Fibergy bar, a LEAN Formula for weight management and several other related products for healthy diets are included in the LEAN Lifelong product line.  The Sensé product line consists of scientifically developed natural products designed to support healthy skin and hair by providing protection and nourishment on both the inside and outside of the dermal layers of the skin.  The Sensé product line accounted for approximately 12% of net sales for the quarter ended March 30, 2002.

 

In addition to these three principal product lines, USANA develops and makes available to Associates a number of materials to assist them in building their business and selling the products. These resource materials or sales aids, which may be purchased from USANA, include product brochures and business forms designed by USANA and printed by outside publishers.  Each major product line incorporates specifically designed sales aids.  From time to time we contract with authors and publishers to provide books, tapes and other items dealing with health and personal motivation and make these available to Associates. USANA also writes and develops materials for audio and videotapes, which are produced by third parties. New Associates are required to purchase a starter kit, containing USANA training materials, that assists them in starting and growing their business.  Affinity and identity are also furthered through the sale of logo merchandise such as clothing, caps, mugs, and other products. Associates do not earn commissions on sales aids, starter kits or logo merchandise.

 

The fiscal year end of USANA is the Saturday closest to December 31 of each year.  Fiscal year 2002 will end on December 28, 2002.  Fiscal year 2001 ended on December 29, 2001.

 

Results of Operations

 

Quarters Ended March 30, 2002 and March 31, 2001

 

Net Sales.  Net sales increased 3.7% to $28.6 million for the quarter ended March 30, 2002, an increase of $1.0 million from the $27.6 million reported for the comparable quarter in 2001.  The increase in net sales can be attributed to sales from our Japan market that commenced operations in the fourth quarter of 2001 and strong Associate enrollments in our more mature markets during the first quarter of 2002.

 

The increase in sales was partially offset by weaker foreign currencies, relative to the U. S. dollar, which negatively affected the translation of sales in foreign markets.  Sales would have been approximately $383,000 higher had foreign currency exchange rates in the first quarter of 2002 been comparable to the rates present in the first quarter of 2001.  Additionally, a price increase in our Australia-New Zealand market took place during the first quarter of 2002; however, lower unit volume offset the price increase and, as a result, only modest top line progress occurred in this market.

 

11

 

The following table illustrates the change in sales by market for the quarters ended March 31, 2001 and March 30, 2002 (sales information for the United Kingdom are incorporated in the results for the United States):

 

		Sales By Market (in thousands) Quarter Ended
Market		March 31, 2001					March 30, 2002					Change from Prior Year			Percent Change
United States		$	16,051		58.1	%	$	15,932		55.7	%	$	(119	)	(0.7%	)
Canada		6,807			24.7	%	7,198			25.1	%	391			5.7	%
Australia-New Zealand		3,467			12.5	%	3,480			12.2	%	13			0.4	%
Hong Kong		1,289			4.7	%	1,176			4.1	%	(113		)	(8.8%	)
Japan		—			0.0	%	836			2.9	%	836			N/A
Consolidated		$	27,614		100.0	%	$	28,622		100.0	%	$	1,008		3.7	%

 

Gross Profit.  Gross profit increased to 73.1% of net sales for the quarter ended March 30, 2002 from 71.1% for the comparable quarter in 2001.  The increase in gross profit can be attributed to:

 

•                  Improved procurement efficiencies and inventory management,

 

•                  The price increase in the Australia-New Zealand market, and

 

•                  Sales in Japan which are priced to yield higher gross margins.

 

These factors that led to an increase in gross profit were partially offset by a higher percentage of sales aids sold in the first quarter of 2002 compared to the same period in 2001.  The increase in sales aids sold is a result of the strong Associate enrollments during the first quarter of 2002.  Revenues from sales aids and starter kits are priced to yield lower gross profit margins as compared to our other products.

 

Associate Incentives.  Associate incentives decreased to 37.5% of net sales for the quarter ended March 30, 2002 from 38.0% for the comparable quarter in 2001.  The decrease in Associate incentives can be primarily attributed to increased sales from our Japan market.  In a newly opened market like Japan, incentives run at a slightly lower than normal rate for a short period of time while Associates learn how to build an efficient and successful business.  The higher percentage of sales aids sold in the first quarter of 2002, which USANA does not pay commissions on, also contributed to lower Associate incentives.  We expect that Associate incentives, as a percentage of net sales, will trend towards historical levels in the next few quarters.

 

Selling, General and Administrative Expenses.  Selling, general and administrative expenses increased to 28.1% of net sales for the quarter ended March 30, 2002 from 27.4% for the comparable quarter in 2001.  The increase in selling, general and administrative expenses as a percentage of net sales can be primarily attributed to the costs related to the proposed transaction involving the sale of assets to the Company’s founder and increased costs to support the Japan market during the first quarter of 2002.  The sale of assets transaction was terminated subsequent to the end of the first quarter of 2002.  USANA still serviced its Japan customers through a direct export program from the United States during the first quarter of 2001.

 

Other Income (Expense).  Foreign currency exchange loss (a component of “Other, net”) decreased by $385,000 in the first quarter of 2002 when compared to the first quarter of 2001.  Additionally, interest expense decreased $161,000 for the first quarter of 2002 when compared to the same period in 2001.  This decrease is a result of lower interest rates and reduced debt levels throughout the first quarter of 2002.

 

12

 

Net Earnings.  Net earnings increased 137.2% to $1.1 million for the quarter ended March 30, 2002, an increase of $646,000 from the $471,000 reported for the comparable quarter in 2001.  The increase in net earnings can be attributed to:

 

•                  Increased sales,

 

•                  Better operating margins,

 

•                  The decrease in foreign currency exchange losses, and

 

•                  Lower interest expense.

 

Diluted earnings per share increased $0.07 to $0.12 for the first quarter of 2002 from $0.05 for the comparable quarter in 2001.

 

Liquidity and Capital Resources

 

USANA has historically financed growth with cash flows from operations. In the first quarter of 2002, USANA generated net cash flows from operations of $3.2 million compared to $5.3 million for the first quarter in 2001.  Cash and cash equivalents increased to $3.3 million at March 30, 2002 from $2.5 million at December 29, 2001.

 

On March 30, 2002, USANA had net working capital of $1.2 million compared to net working capital of $350,000 at December 29, 2001. The change in net working capital was primarily the result of the increased cash balance and decreased current debt.

 

USANA does not extend credit to its customers, but requires payment prior to shipping, which eliminates significant receivables.

 

USANA has agreements with a financial institution that provided up to $22.5 million in secured credit facilities consisting of a $10 million five-year term loan and a $12.5 million three-year revolving line of credit.  The credit facilities contain restrictive covenants requiring USANA to maintain certain financial ratios.  The credit facilities were amended on April 17, 2002 with an effective date equal to the date of the original credit facilities agreement.  The amended credit facilities changed the computation of the fixed charge coverage ratio.  Given this amendment, as of March 30, 2002, USANA was in compliance with all covenants.  As of March 30, 2002, $7.5 million was outstanding on the 5-year term loan and $2.6 million was outstanding on the line of credit.

 

USANA believes that its current cash balances, the available line of credit and cash provided by operations will be sufficient to cover its needs in the ordinary course of business for the foreseeable future.  If USANA experiences an adverse operating environment or unusual capital expenditure requirements, additional financing may be required.  However, no assurance can be given that additional financing, if required, would be available on favorable terms.  USANA may also require or seek additional financing, including through the sale of its equity securities to finance future expansion into new markets, finance capital acquisitions associated with the growth of USANA and for other reasons.  Any financing which involves the sale of equity securities or instruments convertible into equity securities would result in immediate and possibly significant dilution to existing shareholders.

 

Forward-Looking Statements

 

The statements contained in this Report that are not purely historical are considered to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act.  These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future.  They may be identified by the use of words or phrases such as “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others.  Forward-looking statements include, but are not limited to, statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of our existing assets to fund future operations and capital spending needs.  Readers are cautioned that actual results could differ materially from the

 

13

 

anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our most recent Annual Report on Form 10-K, as amended, pages 24 through 30.  The fact that some of the risk factors may be the same or similar to our past reports filed with the Securities and Exchange Commission means only that the risks are present in multiple periods.  We believe that many of the risks detailed here and in the Company’s SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported.  The fact that certain risks are endemic to the industry does not lessen their significance.  The forward-looking statements contained in this Report are made as of the date of this Report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements.  Among others, risks and uncertainties that may affect our business, financial condition, performance, development and results of operations include:

 

•                  Our ability to attract and maintain a sufficient number of Associates,

 

•                  High turnover of Associates,

 

•                  Our reliance on information technology,

 

•                  Our dependence upon a network marketing system to distribute our products,

 

•                  The fluctuation in the value of foreign currencies against the US dollar,

 

•                  Activities of our independent Associates,

 

•                  Rigorous government scrutiny of network marketing practices,

 

•                  Potential effects of adverse publicity regarding nutritional supplements or the network marketing industry,

 

•                  Reliance on key management personnel, including our President, Chief Executive Officer and Chairman of the Board of Directors, Myron W. Wentz, Ph.D.,

 

•                  Extensive government regulation of the Company’s products and manufacturing,

 

•                  Risks related to our expansion into international markets,

 

•                  Failure of USANA to sustain or manage growth including the failure to continue to develop new products,

 

•                  The adverse effect of USANA’s loss of a high level sponsoring Associate together with a group of leading Associates in that person’s downline,

 

•                  The loss of product market share or Associates to competitors,

 

•                  Potential adverse effects of taxation and transfer pricing regulations,

 

•                  Our reliance on outside suppliers for raw materials,

 

•                  Intellectual property risks particularly applicable to our business, or

 

•                  Product liability claims and other manufacturing activity risks.

 

14

 

Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We conduct our business in several countries and intend to continue to expand our foreign operations. Net sales, earnings from operations and net earnings are affected by fluctuations in currency exchange rates, interest rates and other uncertainties inherent in doing business and selling product in more than one currency. In addition, USANA’s operations are exposed to risks associated with changes in social, political and economic conditions inherent in foreign operations, including changes in the laws and policies that govern foreign investment in countries where it has operations as well as, to a lesser extent, changes in United States laws and regulations relating to foreign trade and investment.

 

Foreign Currency Risks.  Sales outside the United States represented 41.9% and 44.3% of net sales for the quarters ended March 31, 2001 and March 30, 2002, respectively.  Inventory purchases are transacted primarily in U.S. dollars from vendors located in the United States.  The local currency of each international subsidiary is considered the functional currency with all revenue and expenses translated at weighted average exchange rates for reported periods.  Consequently, USANA’s reported sales and earnings are impacted positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar.  Given the uncertainty of exchange rate fluctuations, we cannot estimate the effect of these fluctuations on our future business, product pricing, results of operations or financial condition. Changes in currency exchange rates affect the relative prices at which USANA sells its products.

 

As of March 30, 2002 and during the quarter then ended, USANA had no hedging instruments in place to offset exposure to the Canadian Dollar, Australian Dollar, New Zealand Dollar, Hong Kong Dollar, Japanese Yen, British Pound or Euro, to which, in aggregate, USANA had significant exposure.  We regularly monitor our foreign currency risks and periodically take measures to reduce the impact of foreign exchange fluctuations on our operating results.

 

As a last recourse for hedging currency risk, USANA may elect to adjust prices in non-U.S. markets to reflect changes in foreign currency exchange rates.  However, there can be no assurance that these practices will be successful in eliminating all or substantially all of the risks encountered in connection with our foreign currency transactions.

 

Interest Rate Risks.  USANA currently carries $7.5 million in long-term debt at an effective interest rate of 4.15%.  This long-term debt matures at the rate of $1.5 million for the remainder of 2002, $3.4 million in 2003 and $2.6 million in 2004.  We also have a revolving line of credit with $2.6 million outstanding at March 30, 2002 with a weighted average interest rate of 5.25%. The interest rate is computed at the bank’s Prime Rate or LIBOR adjusted by features specified in our loan agreements, with fixed rate term options of up to six months.  A hypothetical 100 basis point increase in interest rates on all of the above debt would result in an annual after tax increase of interest expense of approximately $62,000, which would not materially affect earnings.

 

 

PART II.   OTHER INFORMATION

 

 

Item 5.    OTHER INFORMATION

 

                On April 9, 2002, the Company terminated an agreement for the sale of operating assets to a company controlled by USANA’s founder, Myron W. Wentz, Ph.D.  The agreement for the sale had been entered into on March 21, 2002 and was subject, among other things, to a submission of the proposal to the vote of the shareholders of the Company.

 

15

 

Item 6.    EXHIBITS AND REPORTS ON FORM 8-K

 

(a)                                  Exhibits.

 

Exhibit Number		Description
3.1		Articles of Incorporation [Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993]
3.2		Bylaws [Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993]
3.3		Amendment to Articles of Incorporation to change name and increase par value [Incorporated by reference to Report on Form 10-Q for the period ended July 1, 2000]
4.1		Specimen Stock Certificate for Common Stock, no par value [Incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993]
10.1		Business Loan Agreement by and between Bank of America National Trust and Savings Association, d/b/a Seafirst Bank (“Seafirst Bank”) and the Company [Incorporated by reference to Report on Form 10-Q for the period ended June 27, 1998]
10.2		Loan Modification Agreement by and between Seafirst Bank and the Company [Incorporated by reference to Report on Form 10-Q for the period ended June 27, 1998]
10.3		Employment Agreement dated June 1, 1997 by and between the Company and Gilbert A. Fuller [Incorporated by reference to Report on Form 10-Q for the period ended June 27, 1998]
10.4		Amended and Restated Long-Term Stock Investment and Incentive Plan [Incorporated by reference to Report on Form 10-Q for the period ended June 27, 1998]
10.5		Promissory Note and Redemption Agreement dated April 28, 1999 [Incorporated by reference to Report on Form 10-Q for the period ended April 3, 1999]
10.6		Stock Pledge Agreement dated April 28, 1999 [Incorporated by reference to Report on Form 10-Q for the period ended April 3, 1999]
10.7		Redemption Agreement dated July 30, 1999 [Incorporated by reference to Report on Form 8-K, filed September 24, 1999]
10.8		Amended Term Note dated March 26, 2001 [Incorporated by reference to Report on Form 10-K, filed March 30, 2001]
10.9		Amended Revolving Note dated March 26, 2001 [Incorporated by reference to Report on Form 10-K, filed March 30, 2001]
10.10		Amended Credit Agreement dated March 26, 2001 [Incorporated by reference to Report on Form 10-K, filed March 30, 2001]
10.11		Purchase Agreement dated March 21, 2002 [Incorporated by reference to Annex A of the Preliminary Schedule 14A, filed March 26, 2002]
10.12		Termination of Purchase Agreement dated April 11, 2002 [Incorporated by reference to Report on Form 10-K/A, filed May 1, 2002]
10.13		Amended Credit Agreement dated April 17, 2002
11.1		Computation of Net Earnings per Share (included in Notes to Consolidated Financial Statements)
99.1		Press Release dated September 21, 1999 [Incorporated by reference to Report on Form 8-K, filed September 24, 1999]
99.2		Press Release dated April 11, 2002 [Incorporated by reference to Report on Form 10-K/A, filed May 1, 2002]

 

16

 

(b)                                 Reports on Form 8-K.

 

The Company filed no current reports on Form 8-K during the quarter ended March 30, 2002.

 

17

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

			USANA HEALTH SCIENCES, INC.
Date:	May 12, 2002			By:	/s/ Gilbert A. Fuller
					Gilbert A. Fuller
					Senior Vice President and
					Chief Financial Officer

 

18